Small RNA combination therapy for lung cancer
Name
Xue-2014-Small RNA combinatio.pdf
Size
1.37 MB
Format
Adobe PDF
Checksum (MD5)
d901518663360355c1bc5ed7c640dfc7
Author(s)
Tammela, Tuomas
Xue, Wen
Dahlman, James E.
Sood, Sabina
Dave, Apeksha
Cai, Wenxin
Chirino, Leilani M.
Yang, Gillian R.
Bronson, Roderick T.
Crowley, Denise G.
Date Issued
August 2014
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences (U.S.)
Citation
Xue, W., J. E. Dahlman, T. Tammela, O. F. Khan, S. Sood, A. Dave, W. Cai, et al. “Small RNA Combination Therapy for Lung Cancer.” Proceedings of the National Academy of Sciences 111, no. 34 (August 11, 2014): E3553–E3561.
Version
Final published version
Abstract
MicroRNAs (miRNAs) and siRNAs have enormous potential as cancer therapeutics, but their effective delivery to most solid tumors has been difficult. Here, we show that a new lung-targeting nanoparticle is capable of delivering miRNA mimics and siRNAs to lung adenocarcinoma cells in vitro and to tumors in a genetically engineered mouse model of lung cancer based on activation of oncogenic Kirsten rat sarcoma viral oncogene homolog (Kras) and loss of p53 function. Therapeutic delivery of miR-34a, a p53-regulated tumor suppressor miRNA, restored miR-34a levels in lung tumors, specifically down-regulated miR-34a target genes, and slowed tumor growth. The delivery of siRNAs targeting Kras reduced Kras gene expression and MAPK signaling, increased apoptosis, and inhibited tumor growth. The combination of miR-34a and siRNA targeting Kras improved therapeutic responses over those observed with either small RNA alone, leading to tumor regression. Furthermore, nanoparticle-mediated small RNA delivery plus conventional, cisplatin-based chemotherapy prolonged survival in this model compared with chemotherapy alone. These findings demonstrate that RNA combination therapy is possible in an autochthonous model of lung cancer and provide preclinical support for the use of small RNA therapies in patients who have cancer.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1412686111
